We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Medicare is reinforcing its commitment to patient comfort in hospice care with the implementation of new Hospice Outcomes & Patient Evaluation (HOPE) requirements, effective . To support hospice ...

Topline: A Chinese lab is continuing to receive funds from the U.S. to conduct cruel studies on beagles, according to ...

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent ...

CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability ...

Credit: Saiful52/Shutterstock. WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market ...